| dbo:abstract
|
- Robert Roberts (born in Grole, Newfoundland, Canada), is a cardiologist, geneticist, speaker and educator, who is regarded as one of the founders of molecular cardiology, pioneering the genetic causes of heart disease He is currently the chief executive officer of RDS Inc., executive director of the Heart and Vascular Institute and Director of Cardiovascular Genetics and Genomics at Dignity Health at St Joseph's Hospital & Medical Center, Chair of the International Society of Cardiovascular Translational Research at the University of Arizona College of Medicine, and a Professor of Medicine at the University of Arizona College of Medicine. Dr. Roberts’ accomplished career as a geneticist and cardiologist also includes leading the cardiology department at Baylor College of Medicine in Houston for 23 years, serving as the President and CEO of the University of Ottawa Heart Institute, and working with NASA as a cardiology consultant where he cleared astronaut, John Glenn, to take flight into space. Dr. Roberts has been a keynote speaker in over 35 countries including the Opening Plenary Address of the American College of Cardiology, the Japanese College of Cardiology and the Australian and New Zealand Heart Association. His research is noted for developing the first quantitative assay for MBCK, which was the standard for diagnosing heart attacks in patients for more than three decades and continues to be used in many countries. Most of his research career was devoted to genetics and molecular biology of cardiovascular disorders which led him to several important discoveries, including the mapping of the first gene for atrial fibrillation [1997], the first gene for Wolff-Parkinson-White Syndrome (2001) and many others. His 1998 study on arrhythmogenic right ventricular dysplasia (ARVD) among the population of Grand Falls, Newfoundland and Labrador, Canada led to the infamous Texas Vampires incident and resulted in a 5-year suspension from clinical research by Baylor's Institutional Review Board. In 2014, he discovered the first gene for heart attacks (9p21). Dr. Roberts subsequently identified over 200 other genetic factors for increased risk of heart disease in addition to the already commonly associated environmental factors such as cholesterol and smoking which paved the way for predictive genetic testing for heart disease in men and women at any age (not just when symptomatic). He is currently evaluating the test in males and females, 40 – 60 years of age. His current research as CEO of RDS Inc. focuses on developing a genetic test on a microchip for heart disease that scans an individual's genome for a large number of genetic risk factors associated with heart disease. An individual's polygenic risk score is calculated to identify those with an increased risk of heart attacks, in whom primary prevention can be initiated. He served as co-editor of Hurst's The Heart for 25 years, which is the leading practitioner textbook for cardiologists while also being a member of numerous editorial boards for several journals including the current Editor-in-Chief of Current Opinion in Cardiology. For his research contributions, he has received many awards including the Distinguished Scientist of American College of Cardiology and election to the Academy of Scientists of the Royal Society of Canada. As of January 1, 2021, he has over 46,000 citations and a h-index of 105 on Google Scholar. (en)
|
| rdfs:comment
|
- Robert Roberts (born in Grole, Newfoundland, Canada), is a cardiologist, geneticist, speaker and educator, who is regarded as one of the founders of molecular cardiology, pioneering the genetic causes of heart disease His current research as CEO of RDS Inc. focuses on developing a genetic test on a microchip for heart disease that scans an individual's genome for a large number of genetic risk factors associated with heart disease. An individual's polygenic risk score is calculated to identify those with an increased risk of heart attacks, in whom primary prevention can be initiated. (en)
|
